デフォルト表紙
市場調査レポート
商品コード
1790335

頭頸部がん治療の市場規模、シェア、動向分析レポート:治療タイプ別、投与経路別、流通チャネル別、地域別、セグメント予測、2025年~2033年

Head And Neck Cancer Therapeutics Market Size, Share & Trends Analysis Report By Therapy Type (Chemotherapy, Immunotherapy, Targeted Therapy), By Route of Administration, By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2033


出版日
ページ情報
英文 105 Pages
納期
2~10営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=149.53円
頭頸部がん治療の市場規模、シェア、動向分析レポート:治療タイプ別、投与経路別、流通チャネル別、地域別、セグメント予測、2025年~2033年
出版日: 2025年07月04日
発行: Grand View Research
ページ情報: 英文 105 Pages
納期: 2~10営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

頭頸部がん治療市場の概要

頭頸部がん治療の世界市場規模は、2024年に22億7,000万米ドルと推定され、2033年には62億5,000万米ドルに達し、2025~2033年にかけてCAGR 11.95%で成長すると予測されます。頭頸部がんの罹患率の上昇、標的治療や免疫療法による治療に対する需要の増加、診断精度の進歩などにより、市場は拡大しています。

2025年6月、GORTECの第III相REACH検査は、シスプラチンが不適格な頭頸部がん患者を対象に、アベルマブと放射線治療の併用で良好な結果を示しました。同検査は、主要評価項目である無増悪生存期間の延長を達成し、500人以上の登録患者において良好な安全性プロファイルを示しました。個別化がん医療に対する患者や臨床医の意識の高まりは、早期診断と多剤併用療法の採用を加速させています。毒性を抑えた低侵襲治療へのシフトは、新規薬剤クラスへの臨床的嗜好を高めています。臨床検査の拡大と規制当局による承認の迅速化により、主要市場における製品の入手性が向上しています。

ヒトパピローマウイルス(HPV)関連中咽頭がんの有病率の増加は、頭頸部がん治療市場の重要な促進要因として浮上しています。これらのHPV関連サブタイプは、治療に対する反応が異なることが多く、研究やテーラーメード型薬剤開発の増加を促しています。臨床ガイドラインでは、HPVの状態によって治療アプローチを区別する傾向が強まっており、精密治療への需要が高まっています。製薬会社はウイルスのがん化に対処する治療プロトコールに投資しており、治療の展望を広げています。若年成人におけるHPV陽性患者の増加により、疾患人口層が変化し、新たな市場機会が創出されています。HPV関連悪性腫瘍に対する一般市民の認識とスクリーニングの強化は、早期診断と治療開始に寄与しています。

頭頸部がん治療のセグメントでは、併用療法戦略の導入が勢いを増しており、奏効率や生存率の改善が期待されています。免疫療法と化学療法や標的薬剤を組み合わせた治療レジメンは、一次治療と難治性の両方で検査されています。例えば、2025年6月、FDAはPD-L1陽性の頭頸部がん患者に対するキイトルーダを承認し、バイオマーカーによる治療への注目が高まっていることを強調しました。この発表では、PD-L1陰性患者におけるアンメットニーズも強調されています。CEL-SCIのMultikineは、PD-L1の状態に関係なく、標準治療の前に患者を治療することにより、このギャップに対処することを目的としています。早期の免疫応答を刺激するように設計されたマルチカインは、治療へのアクセスを拡大し、多様な患者群にわたって治療成績を改善しうる新規のアプローチです。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 頭頸部がん治療市場の変数、動向、範囲

  • 市場系統の展望
  • 市場力学
    • 市場促進要因分析
    • 市場抑制要因分析
  • ビジネス環境分析
    • 産業分析-ポーターのファイブフォース分析
    • PESTLE分析
    • パイプライン分析
    • 特許満了分析
    • 価格分析

第4章 頭頸部がん治療市場:治療タイプビジネス分析

  • 治療タイプ市場シェア、2024年と2033年
  • 治療タイプセグメントダッシュボード
  • 市場規模、予測、動向分析(治療タイプ別、2021~2033年)
  • 化学療法
  • 免疫療法
  • 標的療法

第5章 頭頸部がん治療市場:投与経路ビジネス分析

  • 投与経路市場シェア、2024年と2033年
  • 投与経路セグメントダッシュボード
  • 市場規模、予測、動向分析、投与経路別、2021~2033年
  • 注射
  • 経口

第6章 頭頸部がん治療市場:流通チャネルビジネス分析

  • 流通チャネル市場シェア、2024年と2033年
  • 流通チャネルセグメントダッシュボード
  • 市場規模、予測、動向分析(流通チャネル別、2021~2033年)
  • 小売薬局と専門薬局
  • 病院薬局
  • オンライン薬局

第7章 頭頸部がん治療市場:地域別、推定・動向分析

  • 地域別市場シェア分析、2024年と2033年
  • 地域別市場ダッシュボード
  • 市場規模と予測動向分析、2021~2033年
  • 北米
    • 国別、2021~2033年
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • 英国
    • ドイツ
    • フランス
    • イタリア
    • スペイン
    • デンマーク
    • スウェーデン
    • ノルウェー
  • アジア太平洋
    • 日本
    • 中国
    • インド
    • オーストラリア
    • 韓国
    • タイ
  • ラテンアメリカ
    • ブラジル
    • アルゼンチン
  • 中東・アフリカ
    • 南アフリカ
    • サウジアラビア
    • アラブ首長国連邦
    • クウェート

第8章 競合情勢

  • 参加者概要
  • 企業の市況分析
  • 企業分類
  • 戦略マッピング
  • 企業プロファイル/上場企業
    • Eli Lilly and Company
    • Sanofi
    • Merck & Co., Inc.
    • Cumberland Pharmaceuticals Inc.
    • Bristol-Myers Squibb Company
    • AstraZeneca
    • Takeda Pharmaceutical Company Limited
    • Teva Pharmaceutical Industries Ltd.
    • F. Hoffmann-La Roche Ltd.
図表

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of abbreviations
  • Table 3 Global head and neck cancer therapeutics market, by region, 2021 - 2033 (USD Million)
  • Table 4 Global head and neck cancer therapeutics market, by therapy type, 2021 - 2033 (USD Million)
  • Table 5 Global head and neck cancer therapeutics market, by route of administration, 2021 - 2033 (USD Million)
  • Table 6 Global head and neck cancer therapeutics market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 7 North America head and neck cancer therapeutics market, by country, 2021 - 2033 (USD Million)
  • Table 8 North America head and neck cancer therapeutics market, by therapy type, 2021 - 2033 (USD Million)
  • Table 9 North America head and neck cancer therapeutics market, by route of administration, 2021 - 2033 (USD Million)
  • Table 10 North America head and neck cancer therapeutics market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 11 U.S. head and neck cancer therapeutics market, by therapy type, 2021 - 2033 (USD Million)
  • Table 12 U.S. head and neck cancer therapeutics market, by route of administration, 2021 - 2033 (USD Million)
  • Table 13 U.S. head and neck cancer therapeutics market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 14 Canada head and neck cancer therapeutics market, by therapy type, 2021 - 2033 (USD Million)
  • Table 15 Canada head and neck cancer therapeutics market, by route of administration, 2021 - 2033 (USD Million)
  • Table 16 Canada head and neck cancer therapeutics market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 17 Mexico head and neck cancer therapeutics market, by therapy type, 2021 - 2033 (USD Million)
  • Table 18 Mexico head and neck cancer therapeutics market, by route of administration, 2021 - 2033 (USD Million)
  • Table 19 Mexico head and neck cancer therapeutics market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 20 Europe head and neck cancer therapeutics market, by country, 2021 - 2033 (USD Million)
  • Table 21 Europe head and neck cancer therapeutics market, by therapy type, 2021 - 2033 (USD Million)
  • Table 22 Europe head and neck cancer therapeutics market, by route of administration, 2021 - 2033 (USD Million)
  • Table 23 Europe head and neck cancer therapeutics market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 24 UK head and neck cancer therapeutics market, by therapy type, 2021 - 2033 (USD Million)
  • Table 25 UK head and neck cancer therapeutics market, by route of administration, 2021 - 2033 (USD Million)
  • Table 26 UK head and neck cancer therapeutics market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 27 Germany head and neck cancer therapeutics market, by therapy type, 2021 - 2033 (USD Million)
  • Table 28 Germany head and neck cancer therapeutics market, by route of administration, 2021 - 2033 (USD Million)
  • Table 29 Germany head and neck cancer therapeutics market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 30 France head and neck cancer therapeutics market, by therapy type, 2021 - 2033 (USD Million)
  • Table 31 France head and neck cancer therapeutics market, by route of administration, 2021 - 2033 (USD Million)
  • Table 32 France head and neck cancer therapeutics market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 33 Italy head and neck cancer therapeutics market, by therapy type, 2021 - 2033 (USD Million)
  • Table 34 Italy head and neck cancer therapeutics market, by route of administration, 2021 - 2033 (USD Million)
  • Table 35 Italy head and neck cancer therapeutics market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 36 Spain head and neck cancer therapeutics market, by therapy type, 2021 - 2033 (USD Million)
  • Table 37 Spain head and neck cancer therapeutics market, by route of administration, 2021 - 2033 (USD Million)
  • Table 38 Spain head and neck cancer therapeutics market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 39 Norway head and neck cancer therapeutics market, by therapy type, 2021 - 2033 (USD Million)
  • Table 40 Norway head and neck cancer therapeutics market, by route of administration, 2021 - 2033 (USD Million)
  • Table 41 Norway head and neck cancer therapeutics market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 42 Denmark head and neck cancer therapeutics market, by therapy type, 2021 - 2033 (USD Million)
  • Table 43 Denmark head and neck cancer therapeutics market, by route of administration, 2021 - 2033 (USD Million)
  • Table 44 Denmark head and neck cancer therapeutics market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 45 Sweden head and neck cancer therapeutics market, by therapy type, 2021 - 2033 (USD Million)
  • Table 46 Sweden head and neck cancer therapeutics market, by route of administration, 2021 - 2033 (USD Million)
  • Table 47 Sweden head and neck cancer therapeutics market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 48 Asia Pacific head and neck cancer therapeutics market, by country, 2021 - 2033 (USD Million)
  • Table 49 Asia Pacific head and neck cancer therapeutics market, by therapy type, 2021 - 2033 (USD
  • Table 50 Asia Pacific head and neck cancer therapeutics market, by route of administration, 2021 - 2033 (USD Million)
  • Table 51 Asia Pacific head and neck cancer therapeutics market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 52 Japan head and neck cancer therapeutics market, by therapy type, 2021 - 2033 (USD Million)
  • Table 53 Japan head and neck cancer therapeutics market, by route of administration, 2021 - 2033 (USD Million)
  • Table 54 Japan head and neck cancer therapeutics market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 55 China head and neck cancer therapeutics market, by therapy type, 2021 - 2033 (USD Million)
  • Table 56 China head and neck cancer therapeutics market, by route of administration, 2021 - 2033 (USD Million)
  • Table 57 China head and neck cancer therapeutics market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 58 India head and neck cancer therapeutics market, by therapy type, 2021 - 2033 (USD Million)
  • Table 59 India head and neck cancer therapeutics market, by route of administration, 2021 - 2033 (USD Million)
  • Table 60 India head and neck cancer therapeutics market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 61 Australia head and neck cancer therapeutics market, by therapy type, 2021 - 2033 (USD Million)
  • Table 62 Australia head and neck cancer therapeutics market, by route of administration, 2021 - 2033 (USD Million)
  • Table 63 Australia head and neck cancer therapeutics market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 64 South Korea head and neck cancer therapeutics market, by therapy type, 2021 - 2033 (USD Million)
  • Table 65 South Korea head and neck cancer therapeutics market, by route of administration, 2021 - 2033 (USD Million)
  • Table 66 South Korea head and neck cancer therapeutics market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 67 Thailand head and neck cancer therapeutics market, by therapy type, 2021 - 2033 (USD Million)
  • Table 68 Thailand head and neck cancer therapeutics market, by route of administration, 2021 - 2033 (USD Million)
  • Table 69 Thailand head and neck cancer therapeutics market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 70 Latin America head and neck cancer therapeutics market, by country, 2021 - 2033 (USD Million)
  • Table 71 Latin America head and neck cancer therapeutics market, by therapy type, 2021 - 2033 (USD Million)
  • Table 72 Latin America head and neck cancer therapeutics market, by route of administration, 2021 - 2033 (USD Million)
  • Table 73 Latin America head and neck cancer therapeutics market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 74 Brazil head and neck cancer therapeutics market, by therapy type, 2021 - 2033 (USD Million)
  • Table 75 Brazil head and neck cancer therapeutics market, by route of administration, 2021 - 2033 (USD Million)
  • Table 76 Brazil head and neck cancer therapeutics market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 77 Argentina head and neck cancer therapeutics market, by therapy type, 2021 - 2033 (USD Million)
  • Table 78 Argentina head and neck cancer therapeutics market, by route of administration, 2021 - 2033 (USD Million)
  • Table 79 Argentina head and neck cancer therapeutics market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 80 Middle East & Africa head and neck cancer therapeutics market, by country, 2021 - 2033 (USD Million)
  • Table 81 Middle East & Africa head and neck cancer therapeutics market, by therapy type, 2021 - 2033 (USD Million)
  • Table 82 Middle East & Africa head and neck cancer therapeutics market, by route of administration, 2021 - 2033 (USD Million)
  • Table 83 Middle East & Africa head and neck cancer therapeutics market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 84 South Africa head and neck cancer therapeutics market, by therapy type, 2021 - 2033 (USD Million)
  • Table 85 South Africa head and neck cancer therapeutics market, by route of administration, 2021 - 2033 (USD Million)
  • Table 86 South Africa head and neck cancer therapeutics market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 87 Saudi Arabia head and neck cancer therapeutics market, by therapy type, 2021 - 2033 (USD Million)
  • Table 88 Saudi Arabia head and neck cancer therapeutics market, by route of administration, 2021 - 2033 (USD Million)
  • Table 89 Saudi Arabia head and neck cancer therapeutics market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 90 UAE head and neck cancer therapeutics market, by therapy type, 2021 - 2033 (USD Million)
  • Table 91 UAE head and neck cancer therapeutics market, by route of administration, 2021 - 2033 (USD Million)
  • Table 92 UAE head and neck cancer therapeutics market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 93 Kuwait head and neck cancer therapeutics market, by therapy type, 2021 - 2033 (USD Million)
  • Table 94 Kuwait head and neck cancer therapeutics market, by route of administration, 2021 - 2033 (USD Million)
  • Table 95 Kuwait head and neck cancer therapeutics market, by distribution channel, 2021 - 2033 (USD Million)

List of Figures

  • Fig. 1 Head and neck cancer therapeutics market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 Market formulation & validation
  • Fig. 8 Market snapshot
  • Fig. 9 Therapeutic approach and application outlook (USD Million)
  • Fig. 10 Competitive landscape
  • Fig. 11 Head and neck cancer therapeutics market dynamics
  • Fig. 12 Head and neck cancer therapeutics market: Porter's five forces analysis
  • Fig. 13 Head and neck cancer therapeutics market: PESTLE analysis
  • Fig. 14 Therapy type market, 2021 - 2033 (USD Million)
  • Fig. 15 Chemotherapy market, 2021 - 2033 (USD Million)
  • Fig. 16 Immunotherapy market, 2021 - 2033 (USD Million)
  • Fig. 17 Targeted therapy market, 2021 - 2033 (USD Million)
  • Fig. 18 Route of administration market, 2021 - 2033 (USD Million)
  • Fig. 19 Injectable market, 2021 - 2033 (USD Million)
  • Fig. 20 Oral market, 2021 - 2033 (USD Million)
  • Fig. 21 Distribution channel market, 2021 - 2033 (USD Million)
  • Fig. 22 Retail and Specialty Pharmacies market, 2021 - 2033 (USD Million)
  • Fig. 23 Hospital pharmacies market, 2021 - 2033 (USD Million)
  • Fig. 24 Online pharmacies market, 2021 - 2033 (USD Million)
  • Fig. 25 Head and neck cancer therapeutics market revenue, by region
  • Fig. 26 Regional marketplace: Key takeaways
  • Fig. 27 North America Head and neck cancer therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 28 U.S. country dynamics
  • Fig. 29 U.S. Head and neck cancer therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 30 Canada country dynamics
  • Fig. 31 Canada Head and neck cancer therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 32 Mexico country dynamics
  • Fig. 33 Mexico Head and neck cancer therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 34 Europe Head and neck cancer therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 35 UK country dynamics
  • Fig. 36 UK Head and neck cancer therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 37 Germany country dynamics
  • Fig. 38 Germany Head and neck cancer therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 39 France country dynamics
  • Fig. 40 France Head and neck cancer therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 41 Italy country dynamics
  • Fig. 42 Italy Head and neck cancer therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 43 Spain country dynamics
  • Fig. 44 Spain Head and neck cancer therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 45 Norway country dynamics
  • Fig. 46 Norway Head and neck cancer therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 47 Sweden country dynamics
  • Fig. 48 Sweden Head and neck cancer therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 49 Denmark country dynamics
  • Fig. 50 Denmark Head and neck cancer therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 51 Asia Pacific Head and neck cancer therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 52 Japan country dynamics
  • Fig. 53 Japan Head and neck cancer therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 54 China country dynamics
  • Fig. 55 China Head and neck cancer therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 56 India country dynamics
  • Fig. 57 India Head and neck cancer therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 58 Australia country dynamics
  • Fig. 59 Australia Head and neck cancer therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 60 South Korea country dynamics
  • Fig. 61 South Korea Head and neck cancer therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 62 Thailand country dynamics
  • Fig. 63 Thailand Head and neck cancer therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 64 Latin America Head and neck cancer therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 65 Brazil country dynamics
  • Fig. 66 Brazil Head and neck cancer therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 67 Argentina country dynamics
  • Fig. 68 Argentina Head and neck cancer therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 69 MEA Head and neck cancer therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 70 South Africa country dynamics
  • Fig. 71 South Africa Head and neck cancer therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 72 Saudi Arabia country dynamics
  • Fig. 73 Saudi Arabia Head and neck cancer therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 74 UAE country dynamics
  • Fig. 75 UAE Head and neck cancer therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 76 Kuwait country dynamics
  • Fig. 77 Kuwait Head and neck cancer therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 78 Company categorization
  • Fig. 79 Company market position analysis
  • Fig. 80 Strategic framework
目次
Product Code: GVR-2-68038-125-2

Head And Neck Cancer Therapeutics Market Summary

The global head and neck cancer therapeutics market size was estimated at USD 2.27 billion in 2024 and is projected to reach USD 6.25 billion by 2033, growing at a CAGR of 11.95% from 2025 to 2033. The market is growing due to the rising incidence of head and neck cancers, increasing demand for targeted and immunotherapy-based treatments, and advancements in diagnostic precision.

In June 2025, GORTEC's Phase III REACH trial showed positive results for avelumab plus radiotherapy in head and neck cancer patients ineligible for cisplatin. The trial met its primary endpoint of improved progression-free survival and demonstrated a favorable safety profile across over 500 enrolled patients. Growing awareness among patients and clinicians regarding personalized oncology care is accelerating early diagnosis and multi-line therapy adoption. The shift toward minimally invasive treatment options with reduced toxicity drives clinical preference for novel drug classes. Expansion of clinical trials and faster regulatory approvals are enhancing product availability across key markets.

The growing prevalence of human papillomavirus (HPV)-associated oropharyngeal cancers is emerging as a significant driver in the head and neck cancer therapeutics market. These HPV-related subtypes often respond differently to treatment, prompting a rise in research and tailored drug development. Clinical guidelines increasingly differentiate therapeutic approaches based on HPV status, fueling demand for precision therapies. Pharmaceutical companies are investing in treatment protocols that address viral oncogenesis, expanding the therapeutic landscape. The increasing incidence of HPV-positive cases among younger adults has shifted the disease demographic, creating new market opportunities. Enhanced public awareness and screening for HPV-related malignancies contribute to earlier diagnosis and treatment initiation.

Adopting combination therapy strategies is gaining momentum in the head and neck cancer therapeutics space, offering improved response rates and survival outcomes. Treatment regimens integrating immunotherapy with chemotherapy or targeted agents are being tested in both first-line and refractory settings. For instance, in June 2025, the FDA approved Keytruda for PD-L1-positive head and neck cancer patients, highlighting the growing focus on biomarker-based therapies. The announcement also emphasized the unmet need in PD-L1-negative patients. CEL-SCI's Multikine aims to address this gap by treating patients before standard therapies, regardless of PD-L1 status. Designed to stimulate an early immune response, Multikine represents a novel approach that could broaden treatment access and improve outcomes across diverse patient groups.

Global Head And Neck Cancer Therapeutics Market Report Segmentation

This report forecasts revenue growth at the global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global head and neck cancer therapeutics market report based on therapy type, route of administration, distribution channel, and region:

  • Therapy Type Outlook (Revenue, USD Million, 2021 - 2033)
  • Chemotherapy
  • Immunotherapy
  • Targeted Therapy
  • Route of Administration Outlook (Revenue, USD Million, 2021 - 2033)
  • Injectable
  • Oral
  • Distribution Channel Outlook (Revenue, USD Million, 2021 - 2033)
  • Retail and Specialty Pharmacies
  • Hospital Pharmacies
  • Online Pharmacies
  • Regional Outlook (Revenue, USD Million, 2021 - 2033)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Denmark
    • Sweden
    • Norway
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Thailand
  • Latin America
    • Brazil
    • Argentina
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Therapy Type
    • 1.2.2. Route of Administration
    • 1.2.3. Distribution Channel
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Research Methodology
  • 1.5. Information Procurement
    • 1.5.1. Purchased Database
    • 1.5.2. GVR's Internal Database
    • 1.5.3. Secondary Sources
    • 1.5.4. Primary Research
  • 1.6. Information Analysis
    • 1.6.1. Data Analysis Models
  • 1.7. Market Formulation & Data Visualization
  • 1.8. Model Details
    • 1.8.1. Commodity Flow Analysis
  • 1.9. List of Secondary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Head and Neck Cancer Therapeutics Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. Business Environment Analysis
    • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
      • 3.3.1.1. Supplier Power
      • 3.3.1.2. Buyer Power
      • 3.3.1.3. Substitution Threat
      • 3.3.1.4. Threat of New Entrants
      • 3.3.1.5. Competitive Rivalry
    • 3.3.2. PESTLE Analysis
    • 3.3.3. Pipeline Analysis
    • 3.3.4. Patent Expiry Analysis
    • 3.3.5. Pricing Analysis

Chapter 4. Head and Neck Cancer Therapeutics Market: Therapy Type Business Analysis

  • 4.1. Therapy Type Market Share, 2024 & 2033
  • 4.2. Therapy Type Segment Dashboard
  • 4.3. Market Size & Forecasts and Trend Analysis, by Therapy Type, 2021 to 2033 (USD Million)
  • 4.4. Chemotherapy
    • 4.4.1. Chemotherapy Market, 2021 - 2033 (USD Million)
  • 4.5. Immunotherapy
    • 4.5.1. Immunotherapy Market, 2021 - 2033 (USD Million)
  • 4.6. Targeted Therapy
    • 4.6.1. Targeted Therapy Market, 2021 - 2033 (USD Million)

Chapter 5. Head and Neck Cancer Therapeutics Market: Route of Administration Business Analysis

  • 5.1. Route of Administration Market Share, 2024 & 2033
  • 5.2. Route of Administration Segment Dashboard
  • 5.3. Market Size & Forecasts and Trend Analysis, by Route of administration, 2021 to 2033 (USD Million)
  • 5.4. Injectable
    • 5.4.1. Injectable Market, 2021 - 2033 (USD Million)
  • 5.5. Oral
    • 5.5.1. Oral Market, 2021 - 2033 (USD Million)

Chapter 6. Head and Neck Cancer Therapeutics Market: Distribution Channel Business Analysis

  • 6.1. Distribution Channel Market Share, 2024 & 2033
  • 6.2. Distribution Channel Segment Dashboard
  • 6.3. Market Size & Forecasts and Trend Analysis, by Distribution channel, 2021 to 2033 (USD Million)
  • 6.4. Retail and Specialty Pharmacies
    • 6.4.1. Retail and Specialty Pharmacies Market, 2021 - 2033 (USD Million)
  • 6.5. Hospital Pharmacies
    • 6.5.1. Hospital Pharmacies Market, 2021 - 2033 (USD Million)
  • 6.6. Online Pharmacies
    • 6.6.1. Online Pharmacies Market, 2021 - 2033 (USD Million)

Chapter 7. Head and Neck Cancer Therapeutics Market: Regional Estimates & Trend Analysis

  • 7.1. Regional Market Share Analysis, 2024 & 2033
  • 7.2. Regional Market Dashboard
  • 7.3. Market Size & Forecasts Trend Analysis, 2021 to 2033:
  • 7.4. North America
    • 7.4.1. North America Head and Neck Cancer Therapeutics Market Estimates and Forecasts, By Country, 2021 - 2033 (USD Million)
    • 7.4.2. U.S.
      • 7.4.2.1. Key Country Dynamics
      • 7.4.2.2. Route of Administration Disease Prevalence
      • 7.4.2.3. Regulatory Framework
      • 7.4.2.4. Reimbursement Framework
      • 7.4.2.5. U.S. Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.4.3. Canada
      • 7.4.3.1. Key Country Dynamics
      • 7.4.3.2. Route of Administration Disease Prevalence
      • 7.4.3.3. Regulatory Framework
      • 7.4.3.4. Reimbursement Framework
      • 7.4.3.5. U.S. Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.4.4. Mexico
      • 7.4.4.1. Key Country Dynamics
      • 7.4.4.2. Route of Administration Disease Prevalence
      • 7.4.4.3. Regulatory Framework
      • 7.4.4.4. Reimbursement Framework
      • 7.4.4.5. Mexico Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5. Europe
    • 7.5.1. Europe Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.2. UK
      • 7.5.2.1. Key Country Dynamics
      • 7.5.2.2. Route of Administration Disease Prevalence
      • 7.5.2.3. Regulatory Framework
      • 7.5.2.4. Reimbursement Framework
      • 7.5.2.5. Uk Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.3. Germany
      • 7.5.3.1. Key Country Dynamics
      • 7.5.3.2. Route of Administration Disease Prevalence
      • 7.5.3.3. Regulatory Framework
      • 7.5.3.4. Reimbursement Framework
      • 7.5.3.5. Germany Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.4. France
      • 7.5.4.1. Key Country Dynamics
      • 7.5.4.2. Route of Administration Disease Prevalence
      • 7.5.4.3. Regulatory Framework
      • 7.5.4.4. Reimbursement Framework
      • 7.5.4.5. France Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.5. Italy
      • 7.5.5.1. Key Country Dynamics
      • 7.5.5.2. Route of Administration Disease Prevalence
      • 7.5.5.3. Regulatory Framework
      • 7.5.5.4. Reimbursement Framework
      • 7.5.5.5. Italy Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.6. Spain
      • 7.5.6.1. Key Country Dynamics
      • 7.5.6.2. Route of Administration Disease Prevalence
      • 7.5.6.3. Regulatory Framework
      • 7.5.6.4. Reimbursement Framework
      • 7.5.6.5. Spain Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.7. Denmark
      • 7.5.7.1. Key Country Dynamics
      • 7.5.7.2. Route of Administration Disease Prevalence
      • 7.5.7.3. Regulatory Framework
      • 7.5.7.4. Reimbursement Framework
      • 7.5.7.5. Denmark Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.8. Sweden
      • 7.5.8.1. Key Country Dynamics
      • 7.5.8.2. Route of Administration Disease Prevalence
      • 7.5.8.3. Regulatory Framework
      • 7.5.8.4. Reimbursement Framework
      • 7.5.8.5. Sweden Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.9. Norway
      • 7.5.9.1. Key Country Dynamics
      • 7.5.9.2. Route of Administration Disease Prevalence
      • 7.5.9.3. Regulatory Framework
      • 7.5.9.4. Reimbursement Framework
      • 7.5.9.5. Norway Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.6. Asia Pacific
    • 7.6.1. Asia Pacific Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.6.2. Japan
      • 7.6.2.1. Key Country Dynamics
      • 7.6.2.2. Route of Administration Disease Prevalence
      • 7.6.2.3. Regulatory Framework
      • 7.6.2.4. Reimbursement Framework
      • 7.6.2.5. Japan Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.6.3. China
      • 7.6.3.1. Key Country Dynamics
      • 7.6.3.2. Route of Administration Disease Prevalence
      • 7.6.3.3. Regulatory Framework
      • 7.6.3.4. Reimbursement Framework
      • 7.6.3.5. China Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.6.4. India
      • 7.6.4.1. Key Country Dynamics
      • 7.6.4.2. Route of Administration Disease Prevalence
      • 7.6.4.3. Regulatory Framework
      • 7.6.4.4. Reimbursement Framework
      • 7.6.4.5. India Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.6.5. Australia
      • 7.6.5.1. Key Country Dynamics
      • 7.6.5.2. Route of Administration Disease Prevalence
      • 7.6.5.3. Regulatory Framework
      • 7.6.5.4. Reimbursement Framework
      • 7.6.5.5. Australia Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.6.6. South Korea
      • 7.6.6.1. Key Country Dynamics
      • 7.6.6.2. Route of Administration Disease Prevalence
      • 7.6.6.3. Regulatory Framework
      • 7.6.6.4. Reimbursement Framework
      • 7.6.6.5. South Korea Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.6.7. Thailand
      • 7.6.7.1. Key Country Dynamics
      • 7.6.7.2. Route of Administration Disease Prevalence
      • 7.6.7.3. Regulatory Framework
      • 7.6.7.4. Reimbursement Framework
      • 7.6.7.5. Thailand Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.7. Latin America
    • 7.7.1. Latin America Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.7.2. Brazil
      • 7.7.2.1. Key Country Dynamics
      • 7.7.2.2. Route of Administration Disease Prevalence
      • 7.7.2.3. Regulatory Framework
      • 7.7.2.4. Reimbursement Framework
      • 7.7.2.5. Japan Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.7.3. Argentina
      • 7.7.3.1. Key Country Dynamics
      • 7.7.3.2. Route of Administration Disease Prevalence
      • 7.7.3.3. Regulatory Framework
      • 7.7.3.4. Reimbursement Framework
      • 7.7.3.5. China Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.8. Middle East and Africa
    • 7.8.1. Middle East and Africa Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.8.2. South Africa
      • 7.8.2.1. Key Country Dynamics
      • 7.8.2.2. Route of Administration Disease Prevalence
      • 7.8.2.3. Regulatory Framework
      • 7.8.2.4. Reimbursement Framework
      • 7.8.2.5. South Africa Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.8.3. Saudi Arabia
      • 7.8.3.1. Key Country Dynamics
      • 7.8.3.2. Route of Administration Disease Prevalence
      • 7.8.3.3. Regulatory Framework
      • 7.8.3.4. Reimbursement Framework
      • 7.8.3.5. Saudi Arabia Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.8.4. UAE
      • 7.8.4.1. Key Country Dynamics
      • 7.8.4.2. Route of Administration Disease Prevalence
      • 7.8.4.3. Regulatory Framework
      • 7.8.4.4. Reimbursement Framework
      • 7.8.4.5. UAE Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.8.5. Kuwait
      • 7.8.5.1. Key Country Dynamics
      • 7.8.5.2. Route of Administration Disease Prevalence
      • 7.8.5.3. Regulatory Framework
      • 7.8.5.4. Reimbursement Framework
      • 7.8.5.5. Kuwait Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Participant Overview
  • 8.2. Company Market Position Analysis
  • 8.3. Company Categorization
  • 8.4. Strategy Mapping
  • 8.5. Company Profiles/Listing
    • 8.5.1. Eli Lilly and Company
      • 8.5.1.1. Overview
      • 8.5.1.2. Financial Performance
      • 8.5.1.3. Therapy Type Benchmarking
      • 8.5.1.4. Strategic Initiatives
    • 8.5.2. Sanofi
      • 8.5.2.1. Overview
      • 8.5.2.2. Financial Performance
      • 8.5.2.3. Therapy Type Benchmarking
      • 8.5.2.4. Strategic Initiatives
    • 8.5.3. Merck & Co., Inc.
      • 8.5.3.1. Overview
      • 8.5.3.2. Financial Performance
      • 8.5.3.3. Therapy Type Benchmarking
      • 8.5.3.4. Strategic Initiatives
    • 8.5.4. Cumberland Pharmaceuticals Inc.
      • 8.5.4.1. Overview
      • 8.5.4.2. Financial Performance
      • 8.5.4.3. Therapy Type Benchmarking
      • 8.5.4.4. Strategic Initiatives
    • 8.5.5. Bristol-Myers Squibb Company
      • 8.5.5.1. Overview
      • 8.5.5.2. Financial Performance
      • 8.5.5.3. Therapy Type Benchmarking
      • 8.5.5.4. Strategic Initiatives
    • 8.5.6. AstraZeneca
      • 8.5.6.1. Overview
      • 8.5.6.2. Financial Performance
      • 8.5.6.3. Therapy Type Benchmarking
      • 8.5.6.4. Strategic Initiatives
    • 8.5.7. Takeda Pharmaceutical Company Limited
      • 8.5.7.1. Overview
      • 8.5.7.2. Financial Performance
      • 8.5.7.3. Therapy Type Benchmarking
      • 8.5.7.4. Strategic Initiatives
    • 8.5.8. Teva Pharmaceutical Industries Ltd.
      • 8.5.8.1. Overview
      • 8.5.8.2. Financial Performance
      • 8.5.8.3. Therapy Type Benchmarking
      • 8.5.8.4. Strategic Initiatives
    • 8.5.9. F. Hoffmann-La Roche Ltd.
      • 8.5.9.1. Overview
      • 8.5.9.2. Financial Performance
      • 8.5.9.3. Therapy Type Benchmarking
      • 8.5.9.4. Strategic Initiatives